


Healthcare Industry News: Sensipar/Mimpara
News Release - July 16, 2006
Amgen Announces EVOLVE Trial(TM) To Investigate Impact of Sensipar(R)/Mimpara(R) (cinacalcet HCl) on Mortality and Cardiovascular Morbidity in Secondary Hyperparathyroidism Patients With Chronic Kidney Disease Receiving Dialysis
Source: Amgen
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
